ArticleClinical ophthalmology (Auckland, N.Z.)2014
Matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome.
Article in Clinical ophthalmology (Auckland, N.Z.), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Triad of homocysteine, ROCK2 and vimentin as a convergent biomarker signature in pseudoexfoliation.Journal of translational medicine · 2025Article
- Transforming growth factor-β receptors: versatile mechanisms of ligand activation.Acta pharmacologica Sinica · 2024Review
- Article
- TGF-β Isoforms and Local Environments Greatly Modulate Biological Nature of Human Retinal Pigment Epithelium Cells.Bioengineering (Basel, Switzerland) · 2024Article
- TGF-β-3 Induces Different Effects from TGF-β-1 and -2 on Cellular Metabolism and the Spatial Properties of the Human Trabecular Meshwork Cells.International journal of molecular sciences · 2023Article
- Article
- Article
- Is pseudoexfoliation glaucoma a neurodegenerative disorder?Journal of biosciences · 2021Review
- Regulatory cytokines prescribe the outcome of the inflammation in the process of pseudoexfoliation production.Journal of the Chinese Medical Association : JCMA · 2019Article
- Decorin, Tenascin C, Total Antioxidant, and Total Oxidant Level Changes in Patients with Pseudoexfoliation Syndrome.Journal of ophthalmology · 2018Article
- Serum insulin-like growth factor-1 levels in patients with pseudoexfoliation syndrome and glaucoma.International ophthalmology · 2017Article
- Influence of lymphatic endothelial cells on proliferation and invasiveness of esophageal carcinoma cells in vitro and lymphangiogenesis in vivo.Medical oncology (Northwood, London, England) · 2015Article
- Transforming Growth Factor Beta 3 Modifies Mechanics and Composition of Extracellular Matrix Deposited by Human Trabecular Meshwork Cells.ACS biomaterials science & engineering · 2015Article
- The impact of matrix metalloproteinases and their tissue inhibitors in patients with chronic glaucoma - a literature review.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the study reported in this article was to determine the presence and quantitative differences of matrix metalloproteinase-2 (MMP-2), its tissue inhibitor (TIMP-2) and transforming growth factor beta 1 (TGF-β1) in the aqueous humor and serum samples of patients with pseudoexfoliation (PEX) syndrome.
methodsAqueous humor and serum samples were collected from 32 patients with PEX syndrome (with and without glaucoma) and a control group, who underwent routine cataract surgery. Levels of MMP-2, TIMP-2, and TGF-β1 were determined by specific immunoassays (enzyme-linked immunosorbent assay).
resultsMMP-2, TIMP-2, and TGF-β1 were identified in aqueous humor and serum samples from all groups of patients. The aqueous and serum samples of MMP-2, TIMP-2, and TGF-β1 showed no significant differences between PEX syndrome and control groups. Serum levels of MMP-2, TIMP-2, and TGF-β1 were statistically greater than their aqueous levels (P<0.05), except for TIMP-2 levels in the control group.
conclusionNo statistically significant difference among mean MMP-2, TIMP-2, and TGF-β1 levels in both aqueous humor and serum samples was found between patients with PEX syndrome and the control group. It is important to simultaneously evaluate serum and aqueous samples from patients with PEX syndrome, which is related to an impaired blood-aqueous barrier.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.